Inflammatory bowel disorder(IBD)affects over 5.2 million individuals in North America and Europe alone.IBD is a term used to describe a condition of chronic inflammation in the Gastrointestinal tract-primarily the int...Inflammatory bowel disorder(IBD)affects over 5.2 million individuals in North America and Europe alone.IBD is a term used to describe a condition of chronic inflammation in the Gastrointestinal tract-primarily the intestines.While the exact etiology is not fully understood,it is generally accepted that the cause of the inflammation may be due to an abnormal immune response to the gut bacteria.IBD is a progressive disease and can cause various gastrointestinal-related complications.This makes it crucial to discover new treatments and to improve the treatments that are already available.The aim of the study is to answer the question,“What are the emerging therapies for IBD”?In this section,the currently available therapies for IBD are discussed,among which some have already been shown to be effective against IBD whereas some are still in various stages of clinical trials.These therapies include drugs that affect janus kinase-signal transducer and activator of transcription pathway,drugs that impact anti-adhesion molecules,drugs that inhibit anti-interleukin,drugs that modulate sphingosine-1-phosphate receptor,drugs that inhibit phosphodiesterase-4,and finally a technique known as fecal microbial transplant.Many treatments are available today,and new ones are constantly emerging.Some therapies like phosphodiesterase-4 inhibitors and fecal microbiota transplantation that may be the optimum treatment are still under clinical trials,and more research is required for them to be safe,viable,and beneficial options,whereas others are available for usage by the patient but have adverse complications and side effects such as anti-tumor necrosis factor-αor janus kinase-signal transducer and activator of transcription inhibitors.展开更多
文摘Inflammatory bowel disorder(IBD)affects over 5.2 million individuals in North America and Europe alone.IBD is a term used to describe a condition of chronic inflammation in the Gastrointestinal tract-primarily the intestines.While the exact etiology is not fully understood,it is generally accepted that the cause of the inflammation may be due to an abnormal immune response to the gut bacteria.IBD is a progressive disease and can cause various gastrointestinal-related complications.This makes it crucial to discover new treatments and to improve the treatments that are already available.The aim of the study is to answer the question,“What are the emerging therapies for IBD”?In this section,the currently available therapies for IBD are discussed,among which some have already been shown to be effective against IBD whereas some are still in various stages of clinical trials.These therapies include drugs that affect janus kinase-signal transducer and activator of transcription pathway,drugs that impact anti-adhesion molecules,drugs that inhibit anti-interleukin,drugs that modulate sphingosine-1-phosphate receptor,drugs that inhibit phosphodiesterase-4,and finally a technique known as fecal microbial transplant.Many treatments are available today,and new ones are constantly emerging.Some therapies like phosphodiesterase-4 inhibitors and fecal microbiota transplantation that may be the optimum treatment are still under clinical trials,and more research is required for them to be safe,viable,and beneficial options,whereas others are available for usage by the patient but have adverse complications and side effects such as anti-tumor necrosis factor-αor janus kinase-signal transducer and activator of transcription inhibitors.
